BNTX
BioNTech SE
87.21
+
0.50
0.58%
3 x 87.15
3 x 87.27
bid
ask
3 @ 04:00 PM
87.01-0.20 (0.23%)
Bearish
69
Bullish
144
sentiment
86.89
day range
88.32
86.17
52 week range
125.08
Prev Close86.71
Open87.40
Low86.89
High88.32
Volume348.30K
Avg. Volume589.29K
Market Cap21.02B
Inst. Own18.34%
Beta0.23
Short Ratio4.88
Div & Yield0.00 / 0.00
EPS4.10
P/E21.27
1yr Target118.53
50day MA90.87
200day MA101.01
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
BioNTech SE ADR rises Friday, still underperforms market | news.google.com • |
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology | reuters.com • |
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 | globenewswire.com • |
The 3 Best Bargain Stocks to Buy in Q2 2024 | investorplace.com • |
3 Biotech Stocks to Buy for the Next Bull Run: March 2024 | investorplace.com • |
BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions | seekingalpha.com • |
Profile
...
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-06 | 2024-03 | -0.41 | N/A | N/A | N/A |
2024-03-20 | 2023-12 | 2.64 | 2.05 | -0.59 | -22.35% |
2023-11-06 | 2023-09 | -0.53 | 0.73 | 1.26 | 237.74% |
2023-11-06 | 2023-09 | -0.53 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.75 | -0.86 | -0.11 | -14.67% |
2023-08-07 | 2023-06 | -0.75 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-16 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-15 | HSBC | Downgrade | Buy | Hold |
2023-08-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-07 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-07-31 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 7.45M | 804.11M | 3.11% |
2023-06-29 | Primecap Management Company | 4.66M | 502.94M | 1.94% |
2023-06-29 | Temasek Holdings (Private) Limited | 4.52M | 487.64M | 1.88% |
2023-06-29 | Flossbach von Storch AG | 3.44M | 371.47M | 1.44% |
2023-06-29 | Artisan Partners Limited Partnership | 2.03M | 219.13M | 0.85% |
2023-06-29 | Blackrock Inc. | 1.73M | 186.84M | 0.72% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 2.23M | 241.18M | 0.93% |
2023-07-30 | Primecap Odyssey Aggressive Growth Fund | 1.37M | 149.11M | 0.57% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 1.37M | 165.80M | 0.57% |
2023-09-29 | New Perspective Fund Inc | 800.00K | 86.91M | 0.33% |
2023-09-29 | First Trust NYSE Arca Biotechnology Index Fund | 416.94K | 45.30M | 0.17% |
2023-06-29 | Artisan Mid-Cap Fund | 375.33K | 40.51M | 0.16% |
Dividend
...
Dividend | Date |
---|---|
3.068 | 2022-06-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
BioNTech SE ADR rises Friday, still underperforms market
news.google.com • -
The 3 Best Bargain Stocks to Buy in Q2 2024
investorplace.com • -
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
investorplace.com • -
BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
seekingalpha.com • -
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
investorplace.com • -
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
investorplace.com • -
It's Time! 3 Dodgy Pharma Stocks to Sell in February
investorplace.com • -
3 Pharma Stocks to Sell in February Before They Crash and Burn
investorplace.com • -
Top 10 stocks to buy in 2024
invezz.com • -
BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics
seekingalpha.com • -
BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline
seekingalpha.com • -
Barron's Favorite 10 Stocks for 2024
barrons.com • -
BioNTech Vs. Moderna: Navigating The mRNA Landscape
seekingalpha.com • -
3 Biotech Stocks You'll Regret Not Buying Soon: November 2023
investorplace.com • -
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
investorplace.com • -
BioNTech SE (BNTX) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the move
proactiveinvestors.com • -
BioNTech slashes revenue outlook amid lower Covid vaccine sales
proactiveinvestors.com • -
7 Undervalued Stocks That Analysts Love Right Now
investorplace.com • -
Is BioNTech Stock a Buy Now?
fool.com • -
7 Stocks That Are Heading for a Train Wreck
investorplace.com • -
Pfizer and BioNtech take big write-downs on Covid jab stocks
proactiveinvestors.co.uk • -
7 Innovator Stocks Primed for Exceptional Growth
investorplace.com • -
German court suspends mRNA patent trial against BioNTech
reuters.com • -
US FDA authorizes updated COVID vaccines
reuters.com • -
3 Stocks to Buy For the COVID Resurgence
marketbeat.com • -
UK joins EU in approving XBB.1.5 jab from Pfizer-BioNTech, but others subvariants are emerging
proactiveinvestors.co.uk • -
BioNTech: Not Just Another Jab In The Arm
seekingalpha.com • -
Covid Hospitalizations Jump. So Could Vaccine Demand.
barrons.com • -
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
investorplace.com • -
Why BioNTech Stock Was Sinking Today
fool.com • -
BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioNTech Revenue Plunges on Falling Demand for COVID-19 Vaccines
investopedia.com • -
Biotech Stock Hits 2-Year Low as Vaccine Sales Decline
schaeffersresearch.com • -
BioNTech stock declines as revenue topples on lower demand for Covid vaccine
proactiveinvestors.com • -
Disney, UPS, and More Stocks to Watch This Week
barrons.com • -
BioNTech: Unraveling A Bargain, A Hidden Opportunity In Market Misjudgments
seekingalpha.com • -
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
investorplace.com • -
New Strong Buy Stocks for July 11th
zacks.com • -
3 Ugly Stocks That Actually Hide Beautiful Potential
investorplace.com • -
Why Shares of BioNTech Rose Friday
fool.com • -
7 Deeply Undervalued Growth Stocks to Buy in June
investorplace.com • -
7 Safe Stocks to Buy for an Economic Downward Spiral
investorplace.com • -
BioNTech: Hold Out For More Data (Rating Downgrade)
seekingalpha.com • -
BioNTech braces for weak Q2 as Covid vaccine demand subsides
proactiveinvestors.com • -
BioNTech reports strong 1Q earnings; expands focus beyond Covid-19 vaccines
proactiveinvestors.com • -
Earnings Previews: BioNTech, Tyson Foods, Warner Bros Discovery
247wallst.com •